Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company advancing palazestrant (OP-1250) and a KAT6 inhibitor (OP-3136). At June 30, 2025 the company reported total cash, cash equivalents and marketable securities of $361.9 million (cash and cash equivalents of $52.5 million and marketable securities of $309.4 million) and an available balance of $22.0 million under its loan agreement; management states this liquidity is sufficient to fund the current operating plan for at least the next 12 months. Total assets were $382.0 million with stockholders' equity of $345.2 million.
For the quarter ended June 30, 2025, Olema recorded a net loss of $43.8 million (loss per share $0.51); for the six months the net loss was $74.2 million (loss per share $0.87). Research and development expense was $43.9 million for the quarter and $74.5 million for six months, which included a $10.0 million one-time milestone to Aurigene. The company drew $3.0 million under its Credit Facility and continues collaborations with Novartis and Pfizer to supply CDK4/6 inhibitors for clinical trials; it completed a 2024 private placement that generated approximately $237.0 million net proceeds and maintains an at-the-market program with $150.0 million capacity.
Olema Pharmaceuticals reported its financial results for the quarter ended June 30, 2025 and furnished a press release and an investor presentation as exhibits to this Current Report. The filing identifies the press release as Exhibit 99.1, the investor presentation as Exhibit 99.2, and the cover page interactive data file as Exhibit 104. The company states these materials are being furnished and are not deemed "filed" under Section 18 of the Exchange Act.
The 8-K does not include numerical financial metrics within the text; investors seeking revenue, earnings, or other performance figures must review the attached Exhibit 99.1 press release or Exhibit 99.2 presentation or consult the company website where the presentation was made available.